American Oncology Network, Inc.
American Oncology Network, Inc. (AONC) Stock Overview
Explore American Oncology Network, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
291.7M
P/E Ratio
-21.72
EPS (TTM)
$-0.89
ROE
0.25%
AONC Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of American Oncology Network, Inc. (AONC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 38.43, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.45.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -21.72 and a market capitalization of 291.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
American Oncology Network, Inc., through its subsidiaries, provides oncology services in the United States. The company provides various services to patients, including laboratory services for routine and specialized testing; in-house professional and technical pathology services with complete, accurate and timely pathology reports; in-house specialty pharmacy services with patient education, financial assistance, and 24/7 patient assistance; and care management support services including nutrition guidance. The company was incorporated in 2017 and is based in Fort Myers, Florida.
Todd Schonherz
1,914
14543 Global Parkway, Fort Myers, FL
2021